SCHEMBL15834786

SCHEMBL15834786

Cc1cc2nc(N)oc2cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
NUDT1 P36639 2/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
PIK3CG P48736 1/20 0.50
LCK P06239 1/20 0.43
SMN1; SMN2 Q16637 7/20 0.39
ALDH1A1 P00352 5/20 0.39
TP53 P04637 2/20 0.39
TSHR P16473 2/20 0.39
CYP3A4 P08684 1/20 0.39
FABP6 P51161 1/20 0.39
KDM4E B2RXH2 6/20 0.37
RAB9A P51151 5/20 0.37
NPC1 O15118 4/20 0.37
HSD17B10 Q99714 4/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22561724 0.84 MAPT (0.44) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL862784 0.77 L3MBTL1 (0.48) MAPTLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL31486630 0.77 L3MBTL1 (0.48) MAPTLMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL31119200 0.75 MAPT (0.61) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL12261 0.75 MAPT (0.61) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL557792 0.75 PIK3CG (0.61) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL6738898 0.74 ALDH1A1 (0.41) MAPTLMNACYP1A2THRBALOX15
SCHEMBL10981532 0.74 MAPT (0.60) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL19270393 0.74 PIK3CG (0.46) MAPTNUDT1LMNACYP1A2THRB
SCHEMBL31486514 0.74 PSMB8 (0.54) MAPTLMNAALOX15SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113768935-A Prophylactic and/or therapeutic agent for immune diseases 大鹏药品工业株式会社 2021-12-10 CN disclosed
CN-107206001-B Prophylactic and/or therapeutic agent for immune diseases 大鹏药品工业株式会社 2021-09-28 CN disclosed
EP-3120852-B1 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES TAIHO PHARMACEUTICAL CO LTD (JP) 2019-05-01 EP disclosed
US-9951032-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-04-24 US disclosed
US-9951032-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2018-04-24 US disclosed
EP-2947086-B1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2018-01-03 EP disclosed
US-20170369457-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2017-12-28 US disclosed
EP-2934498-B1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2017-11-15 EP disclosed
US-9782412-B2 Preventive and/or therapeutic agent of immune disease TAIHO PHARMACEUTICAL CO., LTD. (JP) 2017-10-10 US disclosed
US-9758497-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2017-09-12 US disclosed
EP-3120852-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES Taiho Pharmaceutical Co., Ltd. (JP) 2017-01-25 EP disclosed
US-20160347728-A1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2016-12-01 US disclosed
US-20160347728-A1 ANTIBACTERIAL COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2016-12-01 US disclosed
US-9428474-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2016-08-30 US disclosed
US-9428474-B2 Antibacterial compounds JANSSEN SCIENCES IRELAND UC (IE) 2016-08-30 US disclosed
US-20160115168-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-04-28 US disclosed
US-20150344449-A1 ANTIBACTERIAL COMPOUNDS JANSSEN-CILAG FRANCE (FR) 2015-12-03 US disclosed
US-20150344449-A1 ANTIBACTERIAL COMPOUNDS JANSSEN-CILAG FRANCE (FR) 2015-12-03 US disclosed
EP-2947086-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2015-11-25 EP disclosed
WO-2014096300-A2 ANTIBACTERIAL COMPOUNDS JANSSEN R&D IRELAND (IE) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344449-A1 ANTIBACTERIAL COMPOUNDS CLPP, CFTR, ELANE MAPT 2107/4885NUDT1 348/4885LMNA 4455/4885
US-20170369457-A1 Antibacterial Compounds CLPP, CFTR, ELANE MAPT 2107/4885NUDT1 348/4885LMNA 4455/4885
US-20160347728-A1 ANTIBACTERIAL COMPOUNDS CLPP, CFTR, ELANE MAPT 2107/4885NUDT1 348/4885LMNA 4455/4885
US-20160115168-A1 NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF BTK, JAK2, SYK MAPT 4777/4885NUDT1 1032/4885LMNA 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.